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Recurrence of cervical intraepithelial lesions
after thermo-coagulation in HIV-positive
and HIV-negative Nigerian women
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Olayinka Olaniyan3, Richard Offiong4, Kayode Obende5, Ayodele Stephen Adewole6, Achara Peter7, Patrick Dakum2
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Abstract
Background: The burden of cervical cancer remains huge globally, more so in sub-Saharan Africa. Effectiveness of
screening, rates of recurrence following treatment and factors driving these in Africans have not been sufficiently
studied. The purpose of this study therefore was to investigate factors associated with recurrence of cervical
intraepithelial lesions following thermo-coagulation in HIV-positive and HIV-negative Nigerian women using Visual
Inspection with Acetic Acid (VIA) or Lugol’s Iodine (VILI) for diagnosis.
Methods: A retrospective cohort study was conducted, recruiting participants from the cervical cancer “see and treat”
program of IHVN. Data from 6 sites collected over a 4-year period was used. Inclusion criteria were: age ≥18 years,
baseline HIV status known, VIA or VILI positive and thermo-coagulation done. Logistic regression was performed to
examine the proportion of women with recurrence and to examine factors associated with recurrence.
Results: Out of 177 women included in study, 67.8 % (120/177) were HIV-positive and 32.2 % (57/177) were
HIV-negative. Recurrence occurred in 16.4 % (29/177) of participants; this was 18.3 % (22/120) in HIV-positive women
compared to 12.3 % (7/57) in HIV-negative women but this difference was not statistically significant (p-value 0.31).
Women aged ≥30 years were much less likely to develop recurrence, adjusted OR = 0.34 (95 % CI = 0.13, 0.92).
Among HIV-positive women, CD4 count <200cells/mm3 was associated with recurrence, adjusted OR = 5.47
(95 % CI = 1.24, 24.18).
Conclusion: Recurrence of VIA or VILI positive lesions after thermo-coagulation occurs in a significant proportion of
women. HIV-positive women with low CD4 counts are at increased risk of recurrent lesions and may be related to
immunosuppression.
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Background
Cervical cancer is the fourth most common cancer in
women and the fourth most common cause of cancer
death worldwide [1]. While its incidence and mortality
are falling in the developed world, mainly as a result of
widespread adoption of cervical cancer screening cover-
ing about 75 % of at-risk women [2–4], in developing
countries, where the burden is most severe, the inci-
dence and mortality remain high and screening covers
only 5 % of at-risk women [5, 6]. Cervical cancer is also
one of the AIDS defining cancers and several studies
suggest that its incidence is higher among HIV positive
individuals [7–11]. In Sub-Saharan Africa the prevalence
of HIV and cervical cancer are high. In Nigeria, the Age
Standardized Incidence Rate (ASR) of cervical cancer
was 34.5 per 100,000 in 2011, making it the second most
common cancer in the country [12] and there were
3.2 million people living with HIV in 2013 (2nd highest
globally) [13].
Cervical cancer occurs after a long asymptomatic pre-
malignant phase, which is referred to as Cervical Intrae-
pithelial Neoplasia (CIN). Majority of low-grade CIN
lesions regress and only some high-grade CIN lesions
progress to invasive cancer [14]. HIV infection is associ-
ated with higher risk of developing CIN; increased risk
of developing a higher grade of disease and more rapid
progression to malignant disease [15]. Treatment of high
grade CIN using excisional or ablative methods are effi-
cacious and substantially reduces risk of cervical cancer
however they can be followed by recurrent disease [16].
Thermo-coagulation is an ablative treatment for pre-
malignant lesions of the cervix developed by Kurt Semm
in 1966 and is increasingly used worldwide. It uses elec-
tricity to generate temperatures of 100–120 °C for abla-
tion of cervical lesions and can be used for all stages of
CIN with minimal side effects. It is also safe, low-cost,
has high client acceptance levels and is thus used in
combination with visual inspection with acetic acid
(VIA) or Lugol’s iodine (VILI) in low-resource settings
as part of a “see and treat” strategy for cervical cancer
screening [17]. Other methods of treating CIN include
cryotherapy and excisional methods such as cold knife
excision, loop excision of the transformation zone and
laser conization.
Recurrence of CIN following treatment occurs in at
least 15 % of cases even with the most effective exci-
sional and ablative treatment modalities; and studies
suggest that recurrence is associated with immunosup-
pression, HIV infection, positive endocervical margins,
CIN grade, persistent HPV infection, glandular involve-
ment and demographic factors [16, 18–26]. Excisional
treatment of cervical lesions is more widely practiced in
developed countries while ablative methods like thermo-
coagulation and cryotherapy have gained ground in
developing countries, yet recurrence of cervical lesions
following treatment is a global problem, and studies have
found ablative treatment to be of similar efficacy as
excisional treatment irrespective of whether follow-up is
based on histology or visual inspection [17]. Factors
associated with recurrence after cervical ablative treat-
ments may differ by populations and the specific method
of ablation used [19, 24, 25, 27–29]. The risk of recur-
rence has been evaluated in developed countries but not
so much in Africa which has a higher prevalence of HIV
and cervical cancer. Previous African studies have
focused on recurrence after treatment with techniques
such as cryotherapy, electrocautery, laser cautery, LLETZ
or cervical conization and there has been no previous
study of recurrence after thermo-coagulation [30–32].
Methods
We conducted an analysis of de-identified data of women
who participated in the cervical cancer “see and treat”
program of the Institute of Human Virology Nigeria
(IHVN) that was implemented in collaboration with 6
hospitals—National Hospital Abuja (NHA), University of
Abuja Teaching Hospital (UATH), Garki Hospital Abuja
(GHA), Federal Medical Centre Keffi (FMCK), Aminu
Table 1 Study sites by numbers screened and inclusion of participants
SITE
NHA, n (%) UATH, n (%) MCHO, n (%) GHA, n (%) FMCK, n (%) AKTH, n (%)
SCREENED, 5190 1979 (38.1) 1792 (34.5) 539 (10.4) 352 (6.8) 393 (7.6 %) 135 (2.6)
HIV Positive = 3212, n (%) 1563 (48.7) 1431 (44.6) 15 (0.4) 39 (1.2) 130 (4.0) 35 (1.1)
HIV Negative = 1978, n (%) 416 (21.0) 361 (18.3) 524 (26.5) 313 (15.8) 263 (13.3) 100 (5.1)
INCLUDED IN STUDY, 177 102 (57.6) 48 (27.1) 8 (4.5) 14 (8.0) 5 (2.8) 0 (0.0)
HIV Positive = 120, n (%) 79 (65.8) 38 (31.7) 1 (0.8) 2 (1.7) 0 (0.0) 0 (0.0)
HIV Negative = 57, n (%) 32 (40.3) 10 (18.5) 7 (12.3) 12 (21.1) 5 (8.8) 0 (0.0)
RECURRENCE, 29 13 (44.8) 13 (44.8) 1 (3.5) 2 (6.9) 0 (0.0) 0 (0.0)
HIV Positive = 22, n (%) 12 (54.5) 10 (45.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
HIV Negative =7, n (%) 1 (14.3) 3 (42.8) 1 (14.3) 2 (28.6) 0 (0.0) 0 (0.0)
Oga et al. BMC Women's Health  (2016) 16:25 Page 2 of 8
Kano Teaching Hospital (AKTH) and Mother and Child
Hospital, Ondo (MCHO)—in different parts of Nigeria
between 2010 and 2014. We evaluated early recurrence of
VIA/VILI positive lesions in women who were previously
screened and treated for cervical precancer using
VIA/VILI.
Women older than 18 years were seen by trained nurses
who obtained informed consent and collected demo-
graphic data, sexual behavior history, obstetrics and
gynecological history, HIV status and if HIV-positive, time
of HIV diagnosis and anti-retroviral treatment history.
The nurses collected participants’ anthropometric mea-
surements, performed a physical examination and a de-
tailed pelvic examination. During the pelvic examination,
they performed VIA and VILI for cervical intraepithelial
lesions and those who tested positive were offered treat-
ment by thermo-coagulation if their lesions met specific
criteria: complete visualization of acetowhite lesion,
Fig. 1 Flowchart of study participants
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Table 2 Baseline characteristics by HIV status
Characteristics HIV-positive (N = 120) n (%) HIV-negative (N = 57) n (%) P value*
Age
< 30 years n (%) 34.0 (28.3) 11.0 (19.3) 0.27
≥ 30 years n (%) 86.0 (71.7) 46.0 (80.7)
Age at first intercourse
< 18 years n (%) 36.0 (30.2) 10.0 (18.2) 0.10
≥ 18 years n (%) 83.0 (69.8) 45.0 (81.8)
Number of Sexual Partners
≤ 1 n (%) 97.0 (82.2) 48.0 (85.7) 0.67
> 1 n (%) 21.0 (17.8) 8.0 (14.3)
Elective Abortions
Ever n (%) 89.0 (76.7) 28.0 (56.0) 0.01*
Never n (%) 27.0 (23.3) 22.0 (44.0)
Number of Pregnancies
< 5 n (%) 84.0 (70.6) 30.0 (53.6) 0.04*
≥ 5 n (%) 35.0 (29.4) 26.0 (46.4)
Miscarriages
Ever n (%) 9.0 (8.3) 11.0 (21.6) 0.04*
Never n (%) 99.0 (91.7) 40.0 (78.4)
Body Mass Index (BMI), Mean (SD) 24.4 (5.2) 28.9 (6.5) 0.02*
Marital Status
Ever Married n (%) 88.0 (73.3) 47.0 (82.5) 0.26
Never Married n (%) 32.0 (26.7) 10.0 (17.5)
Highest Education
Post-secondary n (%) 52.0 (43.7) 36.0 (63.2) 0.02*
≤ Secondary n (%) 67.0 (56.3) 21.0 (36.8)
Contraceptive use
Ever n (%) 51.0 (42.5) 35.0 (61.4) 0.02*
Never n (%) 69.0 (57.5) 22.0 (38.6)
Genital Lesions (Warts, Sores or Ulcers)
Yes n (%) 9 (40.9) 5 (14.7) 0.06
No n (%) 13 (59.1) 29 (85.3)
Follow up duration in days, Median (Interquartile Range)a 793.5 (758.0) 371.0 (274.0) <.0001*
Losses to follow-up n (%) 47.0 (28.1) 38.0 (40.0) 0.06
CD4 Count (cells/mm3)
< 200 n (%) 22.0 (23.7) –
≥ 200 n (%) 71.0 (76.3)
HAART use
Yes n (%) 105.0 (87.5 %) –
No n (%) 15.0 (12.5 %)
HAART REGIMEN
AZT-3TC-NVP n (%) 49 (53.26) –
EFV-TDF-3TC n (%) 18 (19.57)
NVP-TDF-3TC n (%) 7 (7.61)
AZT-3TC-EFV n (%) 4 (4.35)
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acetowhite lesion occupying less than 3 quadrants or less
than 75 % of the transformation zone, acetowhite
lesion amenable to complete coverage by the tip of the
cryoprobe, potential to achieve full contact between aceto-
white lesion/transformation zone and the cervical probe;
and no suspicion of cancer [33, 34]. Participants were
followed up at 6-monthly intervals and monitored for re-
currence. Women who did not return for their follow up
appointments were contacted by telephone to schedule a
visit for follow up examinations including evaluation for
recurrence of VIA/VILI positive lesions.
Student’s t-test was used to compare continuous vari-
ables between HIV-positive and HIV-negative women
while Fisher’s exact test was used for categorical variables.
Logistic regression was performed to examine the propor-
tion of women with recurrence and to examine factors as-
sociated with recurrence. Results are presented with 95 %
confidence intervals. Analysis of the recurrence of cervical
intraepithelial lesions was limited to women with at least
1 follow-up visit after thermo-coagulation. Multivariable
logistic regression was used to identify risk factors for re-
currence of cervical intraepithelial lesions. The following
variables were evaluated for association with recurrent le-
sions - age, age at first intercourse, number of elective
abortions, pregnancies and number of miscarriages,
number of sexual partners, contraception use and
CD4 count. Covariates with p value less than 0.10, along
with biologically relevant variables, were included in the
final multivariable model in which p value of less than
0.05 was considered statistically significant. Statistical ana-
lyses were performed using SAS® software (version 9.3).
Results
Out of a total of 5190 women screened by VIA or VILI
over a 4-year period, the proportion of VIA/VILI positive
lesions was 7.7 % (398/5190); this was 8.3 % (265/3212)
for HIV-positive women and 6.7 % (133/1978) for HIV-
negative women (p-value 0.05), see Table 1 and Fig. 1.
Among women who were VIA/VILI positive, 65.8 %
(262/398) had thermo-coagulation; of the remaining 136
(34.2 %), 109 (80.1 %) were ineligible for thermo-
coagulation and subsequently referred to a gynecologist,
40 (29.4 %) had poorly visualized lesions, 16 (11.8 %) had
suspected cancer, 63 (46.3 %) had lesions occupying more
than three quarters of the transformation zone and
17 (12.5 %) did not consent. Note that the participants
may have had more than one reason that made them ineli-
gible for treatment by thermo-coagulation. Of those
treated, 67.6 % (177/262) were followed up for at least
6 months (Fig. 1) and 32.4 % (85/262) were lost to follow-
up. Fewer HIV-positive women, 28.1 % (47/167) compared
to 40 % (38/95) of HIV-negative women (p-value 0.06)
were lost to follow-up.
A total of 177 participants who had follow up visit at
6 months were included in the analysis of determinants of
recurrent lesions after VIA/VILI and their baseline char-
acteristics are shown in Table 2. The mean age (SD) of
these participants was 34.9 (7.4) years and median follow
up time was 531 days (IQR = 673). Most of these partici-
pants, 67.8 % (120/177), were HIV-positive and 32.2 %
(57/177) were HIV-negative. Recurrence occurred in
16.4 % (29/177) and this was 18.3 % (22/120) in
HIV-positive women compared to 12.3 % (7/57) in
HIV-negative women but this difference was not statisti-
cally significant (p-value 0.31), see Table 3. Women aged
30 years or older were much less likely to develop recur-
rence, adjusted OR = 0.34 (95 % CI = 0.13, 0.92). Among
HIV-positive women, CD4 cell count <200cells/mm3 was
associated with recurrence, adjusted OR = 5.47 (95 % CI =
1.24, 24.18) (Table 4).
Discussion
In this study from Sub-Saharan Africa to evaluate efficacy
of thermo-coagulation treatment for VIA/VILI positive
cervical lesions, we found that one in six women had a re-
current lesion after treatment and no statistically signifi-
cant difference existed between recurrence in HIV-positive
women compared to HIV-negative women. We also found
that women 30 years of age and older were much less likely
to develop recurrence and among HIV-positive women,
low CD4 count was significantly associated with risk of
recurrence. Previous studies have found an association
between HIV infection and increased risk of recurrence of
CIN following excisional treatment [24, 25, 32].
Our finding that 18.3 % of HIV-positive women in our
study had recurrent VIA/VILI positive lesions after
Table 2 Baseline characteristics by HIV status (Continued)
LPV/r-TDF-3TC n (%) 4 (4.35)
TDF-FTC-EFV n (%) 4 (4.35)
AZT-3TC-LPV/r n (%) 2 (2.17)
D4T-3TC-NVP n (%) 2 (2.17)
TDF-FTC-NVP n (%) 2 (2.17)
AZT Zidovudine, 3TC Lamivudine, NVP Nevirapine, EFV Efavirenz, TDF Tenofovir, LPV/r Lopinavir/Ritonavir, FTC Emtricitabine, D4T Stavudine
*Statistically significant at 0.05 level
aComparison of medians was done using Wilcoxon rank-sum test
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treatment compares favorably with a study in Western
Kenya that found recurrence in about 13 % of women
who have had LLETZ within 12 months of follow up
with colposcopy and biopsy [35]. Other studies have re-
ported much higher recurrence in HIV-positive women
following ablative or excisional treatment. Heard et al.
[36] reported recurrence of 53.9 % after excisional treat-
ment and follow-up with cytology, colposcopy and hist-
ology. Vuyst et al. [37] found recurrence (after follow-up
by cytology) of High-grade Squamous Intraepithelial
Lesions (HSIL) following cryotherapy to be 22.8 %. A
systematic review by Tebeu et al. [26] reported recur-
rence of between 20 and 75 % after excisional treatment
and having been followed up by histology; however,
studies that utilized ablative treatments like cryotherapy
and thermo-coagulation were excluded from analysis.
A few studies have compared recurrence between HIV-
positive and HIV-negative women. Fruchter et al. [38]
found recurrence to occur in 62.0 % of HIV-positive
women compared to 18.0 % of HIV-negative women
36 months after treatment by either ablation or excision.
Bambury et al. [39] reported a recurrence rate of 66.2
cases per 100 person-years in HIV-positive women com-
pared to 3.0 per 100 person-years in HIV-negative women
following treatment by thermo-coagulation or LLETZ.
The main attraction of ablative or excisional treatment
after VIA/VILI is the opportunity to reduce or eliminate
repeated clinic visits. However, these recurrence rates sug-
gest that these treatments may not be effective in the long
run particularly in HIV positive women who are at in-
creased risk of persistent HPV infection. The paradigmatic
“see and treat” approach may therefore be inadequate and
women with VIA/VILI positive lesions may require long
term follow up and treatment of recurrent lesions.
We also found that women who are 30 years of age
or older had lower likelihood of recurrence. Previous
studies of HIV-positive women show a steady decline in
prevalence of VIA/VILI positive lesions with increasing
age, most noticeable after age 30 years [6]. This may be a
reflection of reduced prevalence of HPV infection with in-
creasing age. Host immunity may also affect the likelihood
of recurrence [40], so HIV-positive women may be at
Table 3 Univariate analysis of factors associated with recurrence
(N = 177; recurrence, n = 29)
Recurrence Univariate
OR (95 % CI) P-value
N n (%)
HIV status
Negative 57 7 12.3 1.00 0.31
Positive 120 22 18.3 1.6 (0.60–4.00)
Age category (years)
< 30 45 14 31.1 1.00 0.003*
≥ 30 132 15 11.4 0.28 (0.12–0.65)
Age at first intercourse
< 18 years 46 9 19.6 1.00 0.46
≥ 18 years 128 19 14.9 0.71 (0.30–1.70)
No of Sexual Partners
≤ 1 145 24 16.6 1.00 0.93
> 1 29 5 17.3 1.05 (0.40–3.00)
Elective Abortions:
Never 49 5 10.2 1.00 0.12
Ever 117 24 20.5 2.27 (0.81–6.35)
Number of Pregnancies
< 5 114 22 19.3 1.00 0.19
≥ 5 61 7 11.5 0.54 (0.22–1.35)
Miscarriages
Never 139 27 19.4 1.00 0.15
Ever 20 1 5.0 0.22 (0.03–1.70)
Marital Status
Never Married 42 5 11.9 1.00 0.37
Ever Married 135 24 17.8 1.60 (0.57–4.50)
Highest Education
≤ Secondary 88 16 18.2 1.00 0.54
Post-secondary 88 13 14.8 0.78 (0.35–1.74)
Contraceptive use
Never 91 14 15.4 1.00 0.71
Ever 86 15 17.4 1.16 (0.53–2.58)
Genital Lesions (Warts, Sores or Ulcers)
No 42 7 16.7 1.00 0.14
Yes 14 5 35.7 2.78 (0.71–10.88)
CD4 Count (cells/mm3)a
≥ 200 71 8 11.3 1.00 0.03*
< 200 22 7 31.8 3.68 (1.15–11.73)
aHIV positive*Statistically significant at 0.05 level
Table 4 Multivariable analysis of factors associated with
recurrence (N = 177; recurrence n = 29)
Multivariable
aOR (95 % CI) P-value*
HIV status
Negative 1.00 0.97
Positive 0.98 (0.30–3.17)
Age category (years)
< 30 1.00 0.03*
≥ 30 0.34 (0.13–0.92)
CD4 Count (cells/mm3)
≥ 200 1.00 0.04*
< 200 5.47 (1.24–24.18)
aOR adjusted odds ratio
*Statistically significant at 0.05 level
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higher risk of recurrence than HIV-negative women. We
found that severe immunosuppression, as marked by CD4
cell count of <200/mm3 is associated with recurrence and
this is consistent with the results of several studies of re-
currence in HIV-positive women [35].
Our study provides some insight into the efficacy of
thermo-coagulation treatment of VIA/VILI positive le-
sions in HIV-positive and HIV-negative African women
and suggests a need for a review of screening policies on
account of efficacy of treatment and risk of recurrence.
HIV positive women with positive VIA/VILI positive le-
sions will require close long term follow up because of
their higher risk of recurrence. The classical “see and
treat” approach may be an insufficient screening strategy
in this population because it may be associated with
unacceptably high risk of recurrent lesions.
This study has limitations; it utilizes visual inspection
(with Acetic acid and/or Lugol’s Iodine) without cyto-
logical or histological diagnosis. Although validity of VIA/
VILI as method of screening for premalignant cervical
lesions remains a subject of debate, a recent clinical trial
by Huchko et al. [41] reveals that VIA/VILI provide ac-
ceptable results for cervical cancer screening in resource-
poor settings. However, to improve validity of test results
our study employed a Quality Assurance/Quality Control
(QA/QC) mechanism. We utilized a web-based cervico-
graphy with gynecologist verification in addition to on-site
specialist reviews and peer review among nurses as QA/
QC methods, this process has previously been explained
by Adebamowo et al [42]. Other limitations of this study
include high rate of loss to follow up and short duration
of follow up. It is possible that longer duration of follow
up may reveal even higher recurrence in these women.
Conclusion
Recurrence of VIA or VILI positive lesions after thermo-
coagulation occurs in a significant proportion of women.
HIV-positive women with low CD4 counts are at in-
creased risk of recurrent lesions and may be related to
immunosuppression.
More research on the efficacy of “see and treat” cervical
cancer screening strategy is needed given the increasing
adoption of VIA/VILI particularly as an adjunct to PEPFAR
programs for HIV positive women.
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